Browse KCNG1

Summary
SymbolKCNG1
Namepotassium channel, voltage gated modifier subfamily G, member 1
Aliases Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Note=Colocalizes with KCNB1 at the plasma membrane (PubMed:19074135).
Domain PF02214 BTB/POZ domain
PF00520 Ion transport protein
Function

Potassium channel subunit that does not form functional channels by itself. Can form functional heterotetrameric channels with KCNB1; modulates the delayed rectifier voltage-gated potassium channel activation and deactivation rates of KCNB1 (PubMed:19074135).

> Gene Ontology
 
Biological Process GO:0006813 potassium ion transport
GO:0010959 regulation of metal ion transport
GO:0015672 monovalent inorganic cation transport
GO:0022898 regulation of transmembrane transporter activity
GO:0032409 regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0034762 regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0043266 regulation of potassium ion transport
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0071804 cellular potassium ion transport
GO:0071805 potassium ion transmembrane transport
GO:1901016 regulation of potassium ion transmembrane transporter activity
GO:1901379 regulation of potassium ion transmembrane transport
GO:1902259 regulation of delayed rectifier potassium channel activity
GO:1904062 regulation of cation transmembrane transport
GO:2001257 regulation of cation channel activity
Molecular Function GO:0005216 ion channel activity
GO:0005244 voltage-gated ion channel activity
GO:0005249 voltage-gated potassium channel activity
GO:0005251 delayed rectifier potassium channel activity
GO:0005261 cation channel activity
GO:0005267 potassium channel activity
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015079 potassium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022832 voltage-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0022843 voltage-gated cation channel activity
GO:0046873 metal ion transmembrane transporter activity
Cellular Component GO:0008076 voltage-gated potassium channel complex
GO:0034702 ion channel complex
GO:0034703 cation channel complex
GO:0034705 potassium channel complex
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-112316: Neuronal System
R-HSA-1296071: Potassium Channels
R-HSA-1296072: Voltage gated Potassium channels
Summary
SymbolKCNG1
Namepotassium channel, voltage gated modifier subfamily G, member 1
Aliases Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KCNG1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolKCNG1
Namepotassium channel, voltage gated modifier subfamily G, member 1
Aliases Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KCNG1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKCNG1
Namepotassium channel, voltage gated modifier subfamily G, member 1
Aliases Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KCNG1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7680.14
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0170.229
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6010.455
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.340.68
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5650.718
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.480.447
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.910.255
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5020.652
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.7130.158
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4490.455
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5030.533
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.7040.0162
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KCNG1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKCNG1
Namepotassium channel, voltage gated modifier subfamily G, member 1
Aliases Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KCNG1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKCNG1
Namepotassium channel, voltage gated modifier subfamily G, member 1
Aliases Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KCNG1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KCNG1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKCNG1
Namepotassium channel, voltage gated modifier subfamily G, member 1
Aliases Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KCNG1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKCNG1
Namepotassium channel, voltage gated modifier subfamily G, member 1
Aliases Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KCNG1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKCNG1
Namepotassium channel, voltage gated modifier subfamily G, member 1
Aliases Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KCNG1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKCNG1
Namepotassium channel, voltage gated modifier subfamily G, member 1
Aliases Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KCNG1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.